Plain-English translation of NCT06904170 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
The ALICE study is testing whether a combination of two immunotherapy drugs called durvalumab and tremelimumab can help people with advanced liver cancer (hepatocellular carcinoma). Half of the participants will receive just these two medications, while the other half will also receive chemotherapy delivered directly into the liver's blood vessels. The study will first test safety with 90 patients, then expand to 196 total patients to see if the treatment extends survival.
Advanced liver cancer with a large tumor burden is very difficult to treat, and current standard treatments don't work well enough for many patients. This trial is exploring whether combining immunotherapy drugs—which help the body's immune system fight cancer—either alone or with direct chemotherapy delivery to the liver might offer patients a better chance of survival.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the two immunotherapy medications alone, or those same medications plus chemotherapy infused directly into your liver. You will visit the study site regularly for treatment sessions, blood tests, and imaging scans to monitor how the cancer responds. The study takes place at about 20 locations in France, and your health will be closely monitored by an independent safety team throughout your participation.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
France